Apricus Biosciences Announces Corporate Update and Second Quarter 2015 Financial Results Conference Call

SAN DIEGO, July 30, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's second quarter 2015 financial results will be released on Wednesday, August 5, 2015 after the market close. Company management will host a conference call on Wednesday, August 5, 2015, at 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

To participate by telephone, please dial [phone] (Domestic) or [phone] (International). The conference ID number is 99782011. The live audio webcast can be accessed via the Investors section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 90 days following the live call.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus' lead product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus' marketing partners for Vitaros include Mylan NV, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. Apricus' second-generation room temperature Vitaros is under development. Apricus has completed enrollment in a Phase 2a trial for RayVa(TM), its product candidate for the treatment of the circulatory disorder Raynaud's phenomenon. Additionally, Apricus has initiated a Phase 2b trial for fispemifene, a selective estrogen receptor modulator (SERM) for the treatment of symptomatic secondary hypogonadism in men, and plans to conduct additional studies in other urological conditions.

For further information on Apricus, visit http://www.apricusbio.com.

CONTACT: Institutional / Retail Investors: Matthew Beck
         [e-mail]
         The Trout Group LLC
         [phone]

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire

HUG#1942387